The cascade of care for hepatitis C in Victoria, Australia: a data linkage cohort study

Author:

Snow Kathryn1,MacLachlan Jennifer H.12ORCID,Rowe Stacey34,Higgins Nasra3,Cowie Benjamin C.125

Affiliation:

1. WHO Collaborating Centre for Viral Hepatitis The Peter Doherty Institute for Infection and Immunity Melbourne Victoria Australia

2. Department of Infectious Diseases University of Melbourne Melbourne Victoria Australia

3. Victorian Government Department of Health Melbourne Victoria Australia

4. School of Population Health and Preventive Medicine Monash University Melbourne Victoria Australia

5. Victorian Infectious Diseases Service Royal Melbourne Hospital Melbourne Victoria Australia

Abstract

AbstractBackgroundHighly effective hepatitis C therapies are available in Australia. However, people living with hepatitis C face various barriers to accessing care and treatment.AimsTo identify gaps in the cascade of care for hepatitis C and generate estimates of the number living with untreated infection according to population group, using a representative longitudinal study population.MethodsWe linked hepatitis C notification data from Victoria to national pathology, prescribing and death registry data. We assessed receipt of key clinical services in a large cohort who tested positive for hepatitis C from 1 January 2000 to 31 December 2016, with follow‐up to 30 June 2018. We estimated the number still living with hepatitis C, adjusting for spontaneous clearance and mortality.ResultsThe cohort comprised 45 391 people positive for hepatitis C. Of these, 13 346 (29%) received treatment and an estimated 28% (95% confidence interval (CI): 26–30%) were still living with chronic infection at 30 June 2018, with the remainder still living following spontaneous clearance (30%, 95% CI: 29–32%) or having died (12%, 95% CI: 12–12%). Half (50%) of those still living with hepatitis C were born from 1965 to 1980, and 74% first tested positive before 2011.ConclusionsDespite an enabling policy environment and subsidised therapy, many people in this cohort were not treated. Increased measures may be needed to engage people in care, including those who acquired hepatitis C more than 10 years ago.

Publisher

Wiley

Reference35 articles.

1. Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia

2. The Kirby Institute. Monitoring Hepatitis C Treatment Uptake in Australia: Issue 12. July 2022. Report No. 2022.

3. Australian Institute of Health and Welfare. The First Year of COVID‐19 in Australia: Direct and Indirect Health Effects; 2021.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3